Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Drop in Short Interest

Vaccinex, Inc. (NASDAQ:VCNX) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 34,500 shares, a decline of 31.7% from the September 30th total of 50,500 shares. Based on an average daily volume of 106,300 shares, the short-interest ratio is presently 0.3 days. Approximately 2.5% of the shares of the stock are sold short.

Vaccinex Stock Up 10.7 %

Shares of Vaccinex stock traded up $0.36 during trading on Monday, hitting $3.74. The stock had a trading volume of 171,852 shares, compared to its average volume of 49,938. The stock has a 50 day simple moving average of $4.11 and a 200 day simple moving average of $5.35. Vaccinex has a 1 year low of $1.39 and a 1 year high of $13.45. The company has a market capitalization of $6.47 million, a PE ratio of -0.06 and a beta of 0.96.

Vaccinex (NASDAQ:VCNX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($3.10) EPS for the quarter. The company had revenue of $0.23 million for the quarter.

Insider Transactions at Vaccinex

In other news, Director Albert Friedberg bought 200,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were acquired at an average cost of $6.15 per share, with a total value of $1,230,000.00. Following the completion of the transaction, the director now directly owns 762,415 shares in the company, valued at approximately $4,688,852.25. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired 203,753 shares of company stock valued at $1,247,255 in the last quarter. Insiders own 51.50% of the company’s stock.

Institutional Trading of Vaccinex

A hedge fund recently raised its stake in Vaccinex stock. AIGH Capital Management LLC lifted its position in Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,958 shares of the company’s stock after buying an additional 50,593 shares during the quarter. AIGH Capital Management LLC owned about 6.90% of Vaccinex worth $707,000 as of its most recent filing with the Securities and Exchange Commission. 50.11% of the stock is owned by institutional investors.

About Vaccinex

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.